Literature DB >> 21213587

Quantitative HIV-1 proviral DNA detection: a multicentre analysis.

Anita De Rossi1, Marisa Zanchetta, Francesca Vitone, Guido Antonelli, Patrizia Bagnarelli, Luigi Buonaguro, Maria Rosaria Capobianchi, Massimo Clementi, Isabella Abbate, Filippo Canducci, Alessia Monachetti, Elisabetta Riva, Gabriella Rozera, Carolina Scagnolari, Maria Tagliamonte, Maria Carla Re.   

Abstract

Despite the widespread use of molecular biology techniques, standardized methods for the measurement of HIV-1 proviral DNA are currently lacking and several discordant results are still present in different studies. To assess the clinical meaning of the proviral DNA load, a study group comprising seven different laboratories was set up to standardize a HIV-1 proviral DNA quantification method able to assess the DNA proviral load of the most relevant circulating HIV-1 subtypes. Reference samples (24 cellular samples infected with HIV-1 clade B, and 40 samples of peripheral blood mononuclear cells containing different concentrations of plasmids expressing different HIV-1 clades) were distributed and tested blindly. All laboratories employed hTERT gene as housekeeping gene and primers within the gag gene to quantify different HIV-1 clades. Inter-laboratory results did not differ statistically but showed only minor variations concerning HIV-1 DNA amounts and different HIV clades, with a good agreement among the laboratories participating in the study. Since test standardization represents a key step for future application in clinical practice, further studies of the patients' samples are in progress to establish the real meaning and utility of the proviral DNA load for clinical management of HIV-1 infected patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21213587

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  6 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients.

Authors:  Rute Marcelino; Filipa Gramacho; Francisco Martin; Pedro Brogueira; Nuno Janeiro; Claudia Afonso; Robert Badura; Emília Valadas; Kamal Mansinho; Luís Caldeira; Nuno Taveira; José M Marcelino
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

3.  External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy.

Authors:  Ilaria Vicenti; Filippo Dragoni; Alessia Giannini; Anna Casabianca; Francesca Lombardi; Laura Di Sante; Ombretta Turriziani; Sara Racca; Stefania Paolucci; Alessia Lai; Isabella Bon; Isabella Abbate; Gabriella Rozera; Simone Belmonti; Rossana Scutari; Claudia Alteri; Francesco Saladini; Maurizio Zazzi
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

4.  Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection.

Authors:  Camilla Muccini; Monica Guffanti; Vincenzo Spagnuolo; Massimo Cernuschi; Laura Galli; Alba Bigoloni; Andrea Galli; Andrea Poli; Sara Racca; Antonella Castagna
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

Review 5.  Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.

Authors:  Simone Belmonti; Simona Di Giambenedetto; Francesca Lombardi
Journal:  Diagnostics (Basel)       Date:  2021-12-24

6.  Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial.

Authors:  Helen Payne; Man K Chan; Sarah A Watters; Kennedy Otwombe; Nei-Yuan Hsiao; Abdel Babiker; Avy Violari; Mark F Cotton; Diana M Gibb; Nigel J Klein
Journal:  AIDS Res Ther       Date:  2021-09-29       Impact factor: 2.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.